BIAL, a 100-year-old biopharmaceutical company with a strong commitment to innovation, will be a founding member of the Orphan Therapeutics Accelerator (OTXL), a non-profit biotech established in June 2024 with the aim of addressing the challenges of researching and commercialising therapies for rare diseases, which lead to many promising treatments being abandoned or shelved.
This agreement is part of a set of partnerships that OTXL is developing with global biotechs focused on rare diseases, CROs (Contract Research Organisations), CMDOs (Manufacturing and Development Organisations) and providers of Artificial Intelligence-based platforms, with a view to restoring development of promising therapies that were in clinical trials but were discontinued by the companies working on them due to financial and market challenges.
BIAL, as one of the founding members, will play a key role in the selection, final stages of development and commercialisation of a number of therapeutic programmes, which should be announced in the coming months.
Through strategic funding from BIAL and other partners, OTXL plans to start work in the near term on two to three therapeutic programmes targeting ultra-rare diseases in great need of treatment, then expand to others, utilizing a portion of revenues from commercialising the initial programs. This partnership reinforces BIAL's commitment to working with other pharmaceutical and biotech companies, academia, R&D centres of excellence and patient.
